SAMe 200 mg S-Adenosyl-Methionine

SAMe 200 mg S-Adenosyl-Methionine

Life Extension4.8 (2,252 ratings)
Format:Tablet Quantity: 30 Tablet(s) · 30 servings
Goals
$20.24 $0.67 per serving

Product analysis

50 out of 100

SAMe 200 mg S-Adenosyl-Methionine supplies a compound used in normal metabolism, though that role does not establish routine toxin clearance. The specific form is not disclosed, making comparisons with other preparations harder.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality20

The specific SAMe form is not disclosed. That leaves its quality uncertain and limits close comparisons.

Ingredient Transparency63

The amount of SAMe is clear. Its specific form is missing, leaving the preparation less precisely described.

Value For Money40

SAMe offers limited value for the amount provided. The unspecified preparation gives no clear basis for a quality advantage at that cost.

Customer Satisfaction87

Customer feedback is very positive. Thousands of ratings provide a broad view of satisfaction, without establishing liver-related benefits.

Product Focus72

Liver-related support is the main intended use. SAMe’s role in normal metabolism does not establish routine toxin clearance from this serving.

Format
Tablet
Container
30 Tablet(s)
Per serving
$0.67
Customer rating
4.8 · 2,252 ratings
Report analysis

Goals

Liver & Detox
Impact
High effect
B+ Ingredient FitF PathwaysA- EvidenceA+ Formulation Logic
SAMe · 200 mg
Study evidence
SAMe Supportive 30 studies

Ingredients

IngredientAmount per servingScore
S-Adenosyl-Methionine
200 mg 39
Adults 18–50
Report overview
SAMe · 200 mg OverallScore39
F Active Ingredient Quality & BioavailabilityC Dose, Safety & Label TransparencyD- Value
The serving provides 200 mg of SAMe at a somewhat high cost per 400 mg. Blister packaging is not documented. The active yield is not clearly separated from the salt weight.
How this ingredient is rated

Active Ingredient Quality & Bioavailability17

The SAMe salt form is not specified, leaving its stability unclear. Protective blister packaging is not documented, so moisture protection is unclear.
Stabilized Salt Form
The SAMe salt form is not specified, leaving its stability unclear.
Packaging Integrity
Protective blister packaging is not documented, so moisture protection is unclear.

Dose, Safety & Label Transparency60

A serving lists 200 mg of SAMe. The amount is not clearly distinguished as active SAMe versus salt weight.
Active Dosage Strength
A serving lists 200 mg of SAMe.
Net SAMe Yield Transparency
The amount is not clearly distinguished as active SAMe versus salt weight.

Value40

The cost per 400 mg of SAMe is somewhat high. Enteric coating or delayed release is not documented, leaving protection from stomach acid uncertain.
Price Per 400mg Active Dose
The cost per 400 mg of SAMe is somewhat high. Enteric coating or delayed release is not documented, leaving protection from stomach acid uncertain.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
    Noureddin M; Sander-Struckmeier S; Mato JM · World journal of hepatology · 2020
    Systematic review9 studies pooledLiver & Detox forSAMe
  2. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
    Zhang L; Liu XH; Qi HB; Li Z; Fu XD; Chen L; Shao Y · European review for medical and pharmacological sciences · 2016
    Randomized trial120 participantsLiver & Detox forSAMe
  3. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
    Guo T; Chang L; Xiao Y; Liu Q · PloS one · 2015
    Meta-analysis705 participants11 studies pooledLiver & Detox forSAMe
  4. Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
    Liu GY; Wang W; Jia WD; Xu GL; Ma JL; Ge YS; Yu JH; Sun QK; Meng FL · World journal of surgical oncology · 2014
    Non-randomized trial81 participantsLiver & Detox forSAMe
  5. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
    Mato JM; Cámara J; Fernández de Paz J; Caballería L; Coll S; Caballero A; García-Buey L; Beltrán J; Benita V; Caballería J; Solà R; Moreno-Otero R; Barrao F; Martín-Duce A; Correa JA; Parés A; Barrao E; García-Magaz I; Puerta JL; Moreno J; Boissard G; Ortiz P; Rodés J · Journal of hepatology · 1999
    Randomized trial123 participantsLiver & Detox forSAMe